指南与共识儿科与产科急症呼吸衰竭与机械通气重症综合管理与镇静镇痛

儿童和青少年COVID-19预防与管理指南

Guidelines for the prevention and management of children and adolescents with COVID-19.
指南 / 共识 · Eur J Pediatr · 2022-09-16
一句话结论国际多学科专家组基于GRADE系统更新儿童COVID-19管理指南,涵盖预后因素、瑞德西韦、糖皮质激素、退热药、IVIG、经鼻高流量氧疗或无创通气、母乳喂养、疫苗接种及心理健康。

该指南为2020年COVID-19暴发初期快速建议指南的更新版,由国际多学科专家组制定,纳入更多利益相关者并全面检索最新证据。所有推荐均基于系统评价并采用GRADE系统分级,另以专家判断制定良好实践声明作为补充。更新版指南包含9条推荐和1条良好实践声明,聚焦死亡或儿童重症监护室入住预后因素识别、瑞德西韦、全身糖皮质激素和退热药的使用、静脉注射免疫球蛋白(IVIG)用于儿童多系统炎症综合征、经鼻高流量氧疗或无创通气用于急性低氧性呼吸衰竭、母乳喂养、疫苗接种及儿童心理健康管理。作者鼓励开展更大样本、更长随访的研究以确定全身糖皮质激素、IVIG、无创通气和COVID-19疫苗在儿童和青少年中的有效性和安全性。

要点

  • 更新版指南包含9条推荐和1条良好实践声明,所有推荐均基于系统评价并采用GRADE系统分级。
  • 指南聚焦死亡或儿童重症监护室入住预后因素的识别。
  • 指南涵盖瑞德西韦、全身糖皮质激素和退热药的使用推荐。
  • 指南涵盖IVIG用于儿童多系统炎症综合征、经鼻高流量氧疗或无创通气用于急性低氧性呼吸衰竭的推荐。
  • 指南还涉及母乳喂养、疫苗接种及儿童心理健康管理,作者鼓励开展更大样本、更长随访研究以确定全身糖皮质激素、IVIG、无创通气和COVID-19疫苗的有效性和安全性。

适用人群与场景

  • 儿童和青少年COVID-19的预防与管理。

处置流程与药物剂量

  • 指南推荐涉及瑞德西韦、全身糖皮质激素和退热药的使用,具体剂量与方案原文未给出。
  • 指南推荐涉及IVIG用于儿童多系统炎症综合征,具体剂量与方案原文未给出。
  • 指南推荐涉及经鼻高流量氧疗或无创通气用于急性低氧性呼吸衰竭,具体参数原文未给出。
  • 指南推荐涉及母乳喂养、疫苗接种及儿童心理健康管理,具体方案原文未给出。

研究设计与关键结果

  • 该指南为2020年COVID-19暴发初期快速建议指南的更新版,制定方法为国际多学科专家组纳入更多利益相关者并全面检索最新证据,所有推荐均基于系统评价并采用GRADE系统分级,另以专家判断制定良好实践声明作为补充。
  • 更新版指南包含9条推荐和1条良好实践声明。

证据类型、等级与局限

  • 证据类型:指南;推荐采用GRADE系统分级,另以专家判断制定良好实践声明作为补充。
  • 局限:作者鼓励开展更大样本、更长随访的研究以确定全身糖皮质激素、IVIG、无创通气和COVID-19疫苗在儿童和青少年中的有效性和安全性。

对床旁实践的改变

  • 作者鼓励开展更大样本、更长随访的研究以确定全身糖皮质激素、IVIG、无创通气和COVID-19疫苗在儿童和青少年中的有效性和安全性。

指南或共识出处

  • 指南名称:儿童和青少年COVID-19预防与管理指南(Guidelines for the prevention and management of children and adolescents with COVID-19);发布机构:国际多学科专家组;发表期刊:Eur J Pediatr;年份原文未明确给出。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Children are the future of the world, but their health and future are facing great uncertainty because of the coronavirus disease 2019 (COVID-19) pandemic. In order to improve the management of children with COVID-19, an international, multidisciplinary panel of experts developed a rapid advice guideline at the beginning of the outbreak of COVID-19 in 2020. After publishing the first version of the rapid advice guideline, the panel has updated the guideline by including additional stakeholders in the panel and a comprehensive search of the latest evidence. All recommendations were supported by systematic reviews and graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Expert judgment was used to develop good practice statements supplementary to the graded evidence-based recommendations. The updated guideline comprises nine recommendations and one good practice statement. It focuses on the key recommendations pertinent to the following issues: identification of prognostic factors for death or pediatric intensive care unit admission; the use of remdesivir, systemic glucocorticoids and antipyretics, intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome in children, and high-flow oxygen by nasal cannula or non-invasive ventilation for acute hypoxemic respiratory failure; breastfeeding; vaccination; and the management of pediatric mental health.

CONCLUSION: This updated evidence-based guideline intends to provide clinicians, pediatricians, patients and other stakeholders with evidence-based recommendations for the prevention and management of COVID-19 in children and adolescents. Larger studies with longer follow-up to determine the effectiveness and safety of systemic glucocorticoids, IVIG, noninvasive ventilation, and the vaccines for COVID-19 in children and adolescents are encouraged.

WHAT IS KNOWN: • Several clinical practice guidelines for children with COVID-19 have been developed, but only few of them have been recently updated. • We developed an evidence-based guideline at the beginning of the COVID-19 outbreak and have now updated it based on the results of a comprehensive search of the latest evidence.

WHAT IS NEW: • The updated guideline provides key recommendations pertinent to the following issues: identification of prognostic factors for death or pediatric intensive care unit admission; the use of remdesivir, systemic glucocorticoids and antipyretics, intravenous immunoglobulin for multisystem inflammatory syndrome in children, and high-flow oxygen by nasal cannula or non-invasive ventilation for acute hypoxemic respiratory failure; breastfeeding; vaccination; and the management of pediatric mental health.

来源:Eur J Pediatr,查看原文。版权归原作者所有。

参考来源

  1. Liu E, Smyth RL, Li Q, et al. Guidelines for the prevention and management of children and adolescents with COVID-19. Eur J Pediatr. 2022. PMID: 36109390. doi:10.1007/s00431-022-04615-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。